Cargando…
543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
BACKGROUND: Molnupiravir (MOV, MK-4482, EIDD-2801) is an orally administered prodrug of N-hydroxycytidine (NHC, EIDD-1931), a nucleoside with broad antiviral activity against a range of RNA viruses. MOV acts by driving viral error catastrophe following its incorporation by the viral RdRp into the vi...
Autores principales: | Grobler, Jay, Strizki, Julie, Murgolo, Nicholas, Gao, Wei, Cao, Youfang, Zhang, Ying, Du, Jiejun, Nair, Manoj, Huang, Yaoxing, Luo, Yang, Hazuda, Daria, Ho, David D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644651/ http://dx.doi.org/10.1093/ofid/ofab466.742 |
Ejemplares similares
-
153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022) -
511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
por: Strizki, Julie, et al.
Publicado: (2021) -
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021) -
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
por: Johnson, Matthew G., et al.
Publicado: (2023) -
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)